Manufacturing Techniques of Orally Dissolving Films - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Techniques of Orally Dissolving Films
The manufacture of orally dissolving films is done by various methods such as solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling. The authors discuss these methods and the various parameters in which dissolving films are evaluated.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 70-73

Clinical and regulatory requirement

To indicate bioequivalency of a product to that of existing oral drug, an abbreviated new drug application is required. In-vitro dissolution studies and therapeutic equivalence are considered. Comparative bioequivalence between an orally disintegrating tablet and an ODF can be evaluated. If the ODF exhibits a different target pharmacokinetic profile compared with the existing marketed product, the ODF is considered a new dosage form. For a new dosage form, a new clinical study is required. A new clinical study offers the advantage of three years of marketing exclusivity to the product. Preclinical toxicity studies are not required if the molecule is the same as that of the approved product. Safety, tolerability, and efficacy features are to be demonstrated in such trials. Oral mucosa-irritation testing is carried out in both animal models and humans. The hamster-cheek pouch is the most appropriate model for predicting irritation criteria before testing in humans (12).

Conclusion

ODFs are a possible alternative dosage form to orally disintegrating tablets. These films offer the benefits of pleasant mouthfeel and rapid disintegration in the mouth. Solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling are important manufacturing methods to produce these films.

Renuka Mishra* is an assistant professor, and Avani Amin is a professor in the Department of Pharmaceutics and Pharmaceutical Technology, the Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat, India,

*To whom all correspondence should be addressed.

References

1. S. Borsadia, D. O'Halloran, and J.L. Osborne, Drug Del. Tech. 3 (3), 63–66 (2003).

2. T. Ghosh and W.Pfister, "Intraoral Delivery Systems: An Overview, Current Status and Future Trends," in Drug Delivery to the Oral Cavity: Molecules to Market, T. Ghosh and W. Pfister, Eds. (Taylor & Francis, Florida, CRC Press, 2005), pp. 1–34.

3. P. V. Arnum, "Outsourcing Solid Dosage Manufacturing," Pharm. Technol. 30 (6), 44–52 (2006).

4. R. Mishra and A. Amin, Pharm. Technol. Eur. 19 (10), 35–39 (2007).

5. M. Repka et al., "Hot Melt Extrusion," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, Eds. (Marcel Dekker Inc., New York, Vol. 2, 2nd Edition, 2002), pp. 1488–1504.

6. M.A. Repka and J.W. McGinity, Pharm. Dev. Technol. 6 (3), 297–304 (2001).

7. M. Repka and J.W. McGinity, J. Controlled Release 76 (3), 341–351 (2001).

8. J. Breitenbach, Eur. J. Pharm. Biopharm. 54 (2), 107–117 (2002).

9. A. Arya et al., Int. J. Chem. Tech. Research 2 (1), 578–583 (2010).

10. Gole et al., "Pharmaceutical and Other Dosage Forms," US Patent 5648093, Jul. 1997.

11. R.K. Yang et al., "Thin Film with Non-Self Aggregating Uniform Heterogeneity and Drug Delivery Systems Made Therefrom," US Patent Application 20080226695.

12. R. Mishra and A. Amin, Pharm. Technol. 33 (2), 48–56 (2009).

13. R.P. Dixit, S.P. Puthli, J. Controlled Release 139 (2), 94–107 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here